Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,365 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00059722 | This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | completed | Phase 2 | 160 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Aug 24, 2016 | clinicaltrials |
| NCT00404703 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Based Chemotherapy in Patients With Advanced or Recurrent Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 37 | Hoffmann-La RocheINDUSTRY | 10 | Aug 24, 2016 | clinicaltrials |
| NCT01132664 | Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer | terminated | Phase 1 / Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 6 | Aug 17, 2016 | clinicaltrials |
| NCT01022346 | A Study of RO5217790 in Participants With High Grade Cervical Intraepithelial Neoplasia (CIN) Associated With High Risk Human Papillomavirus (HR-HPV) Infection | completed | Phase 2 | 206 | Hoffmann-La RocheINDUSTRY | 6 | Aug 15, 2016 | clinicaltrials |
| NCT00327535 | A Study of Mircera in Anemic Patients With Non-Small Cell Lung Cancer Receiving First Line Chemotherapy. | completed | Phase 2 | 153 | Hoffmann-La RocheINDUSTRY | 15 | Aug 11, 2016 | clinicaltrials |
| NCT02774278 | A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)(MERIT) | completed | Phase 2 | 264 | Hoffmann-La RocheINDUSTRY | 14 | Aug 8, 2016 | clinicaltrials |
| NCT00162123 | A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies | completed | Phase 2 | 248 | Bristol-Myers SquibbINDUSTRY | 18 | Jul 27, 2016 | clinicaltrials |
| NCT00514943 | BIBW 2992 (Afatinib) in Head & Neck Cancer | completed | Phase 2 | 124 | Boehringer IngelheimINDUSTRY | 4 | Jul 26, 2016 | clinicaltrials |
| NCT01528345 | Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer | terminated | Phase 2 | 97 | Novartis PharmaceuticalsINDUSTRY | 15 | Jul 11, 2016 | clinicaltrials |
| NCT00450892 | Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer | completed | Phase 1 / Phase 2 | 129 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Jul 7, 2016 | clinicaltrials |
| NCT01522612 | Colorectal Cancer (CRC) Cetuximab Elderly Frail | terminated | Phase 2 | 5 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Jun 10, 2016 | clinicaltrials |
| NCT01658527 | TAK-700 in Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jun 10, 2016 | clinicaltrials |
| NCT01013324 | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 67 | SanofiINDUSTRY | 2 | Jun 3, 2016 | clinicaltrials |
| NCT01666977 | Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 36 | AmgenINDUSTRY | 6 | Jun 3, 2016 | clinicaltrials |
| NCT01599949 | A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy | completed | Phase 2 | 120 | Janssen Research & Development, LLCINDUSTRY | 9 | Jun 1, 2016 | clinicaltrials |
| NCT01562990 | Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse | completed | Phase 1 / Phase 2 | 11 | The Lymphoma Academic Research OrganisationOTHER | 2 | May 23, 2016 | clinicaltrials |
| NCT02468076 | Radiofrequency Ablation for Biliopancreatic Malignancy(IGNITE-1) | completed | Phase 2 | 18 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01658436 | BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. | completed | Phase 2 | 31 | Novartis PharmaceuticalsINDUSTRY | 9 | May 2, 2016 | clinicaltrials |
| NCT02338531 | Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer(RHEA) | withdrawn | Phase 2 | 0 | Jules Bordet InstituteOTHER | 2 | Apr 29, 2016 | clinicaltrials |
| NCT00872404 | A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma | terminated | Phase 2 | 37 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00973193 | Preoperative Panitumumab and Radiotherapy in Rectal Cancer(PrePaRad) | terminated | Phase 2 | 20 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01147809 | Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag | completed | Phase 2 | 130 | GlaxoSmithKlineINDUSTRY | 13 | Apr 18, 2016 | clinicaltrials |
| NCT01858662 | Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors | terminated | Phase 2 | 4 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Apr 15, 2016 | clinicaltrials |
| NCT01395017 | Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer(LAPC) | completed | Phase 2 | 202 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 15 | Apr 8, 2016 | clinicaltrials |
| NCT01008475 | EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer(POSEIDON) | completed | Phase 1 / Phase 2 | 232 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 12 | Mar 30, 2016 | clinicaltrials |
| NCT02435121 | A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification | completed | Phase 2 | 1 | SanofiINDUSTRY | 1 | Mar 23, 2016 | clinicaltrials |
| NCT01403636 | A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia | completed | Phase 2 | 167 | SanofiINDUSTRY | 6 | Mar 17, 2016 | clinicaltrials |
| NCT01297491 | Safety and Efficacy of BKM120 in Patients With Metastatic Non-small Cell Lung Cancer(BASALT-1) | completed | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 11, 2016 | clinicaltrials |
| NCT01290926 | Sorafenib Plus Capecitabine Efficacy Assessment in Patients With Advanced Pre-treated Colorectal Cancer(SoMore) | completed | Phase 2 | 97 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT01709487 | Feasibility Study of HIPEC for Patients With Stage III or Only Pleural Stage IV Ovarian Carcinoma in First Line Therapy | completed | Phase 1 / Phase 2 | 19 | Jules Bordet InstituteOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02430363 | Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475 | unknown | Phase 1 / Phase 2 | 58 | Medical Research CouncilOTHER_GOV | 10 | Feb 24, 2016 | clinicaltrials |
| NCT01202591 | Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients(GLOW) | completed | Phase 1 / Phase 2 | 127 | AstraZenecaINDUSTRY | 8 | Feb 11, 2016 | clinicaltrials |
| NCT00297258 | Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma | completed | Phase 2 | 148 | GlaxoSmithKlineINDUSTRY | 5 | Feb 3, 2016 | clinicaltrials |
| NCT00835185 | Study of IMC-11F8 in Participants With Colorectal Cancer | completed | Phase 2 | 44 | Eli Lilly and CompanyINDUSTRY | 2 | Jan 29, 2016 | clinicaltrials |
| NCT01287390 | Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck | completed | Phase 2 | 100 | University Hospital, GhentOTHER | 1 | Jan 27, 2016 | clinicaltrials |
| NCT00889590 | Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)(HR-GCT) | terminated | Phase 2 | 15 | Leiden University Medical CenterOTHER | 2 | Jan 26, 2016 | clinicaltrials |
| NCT00982488 | Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia(START rollover) | completed | Phase 2 | 238 | Bristol-Myers SquibbINDUSTRY | 24 | Jan 22, 2016 | clinicaltrials |
| NCT00900627 | Phase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)(THYME) | completed | Phase 1 / Phase 2 | 330 | AstraZenecaINDUSTRY | 14 | Jan 20, 2016 | clinicaltrials |
| NCT01185847 | A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | Hoffmann-La RocheINDUSTRY | 7 | Jan 1, 2016 | clinicaltrials |
| NCT01028222 | A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation(TEAM) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 14 | Dec 30, 2015 | clinicaltrials |
| NCT01332656 | Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel(OPSALIN) | completed | Phase 2 | 154 | SanofiINDUSTRY | 10 | Dec 21, 2015 | clinicaltrials |
| NCT01360840 | EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer(PERSEUS) | completed | Phase 2 | 180 | EMD SeronoINDUSTRY | 12 | Dec 14, 2015 | clinicaltrials |
| NCT00389155 | First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy | completed | Phase 2 / Phase 3 | 34 | Bristol-Myers SquibbINDUSTRY | 16 | Dec 7, 2015 | clinicaltrials |
| NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer(GALAXY) | terminated | Phase 2 / Phase 3 | 385 | Synta Pharmaceuticals Corp.INDUSTRY | 13 | Nov 5, 2015 | clinicaltrials |
| NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer(Enchant) | completed | Phase 2 | 51 | Synta Pharmaceuticals Corp.INDUSTRY | 8 | Nov 5, 2015 | clinicaltrials |
| NCT01160315 | Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure(Erasme-POF) | completed | Phase 2 / Phase 3 | 118 | Erasme University HospitalOTHER | 3 | Oct 30, 2015 | clinicaltrials |
| NCT00511459 | Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients | completed | Phase 2 | 228 | AmgenINDUSTRY | 13 | Oct 29, 2015 | clinicaltrials |
| NCT00372996 | Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer | terminated | Phase 2 | 219 | PfizerINDUSTRY | 9 | Oct 28, 2015 | clinicaltrials |
| NCT01809171 | Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients | terminated | Phase 2 / Phase 3 | 15 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Oct 21, 2015 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials